REVIEW ARTICLE

Unlocking the Potential of *In-silico* Approaches: Drug Development and Vaccine Design

Priya V Nikam[1], Sanjay Kumar[2*], Sachinkumar D Gunjal[3], Mrunalini H Kulkarni[4], Surya P Singh[5]

[1]*Nagpur College of Pharmacy, Nagpur, Maharashtra, India.*
[2]*Faculty of Pharmacy, Uttar Pradesh University of Medical Sciences, Etawah, Uttar Pradesh, India.*
[3]*Amrutvahini College of Pharmacy, Sangamner, Maharashtra, Savitribai Phule Pune University, Maharashtra, India.*
[4]*School of Pharmacy, Vishwakarma University, Pune, Maharashtra, India.*
[5]*Uttar Pradesh University of Medical Sciences, Etawah, Uttar Pradesh, India.*

Received: 18th September, 2023; Revised: 16th October, 2023; Accepted: 10th November, 2023; Available Online: 25th December, 2023

ABSTRACT

Unmatched in its field, bioinformatics combines several academic fields such as statistics, computer science, mathematics, and biology to create state-of-the-art techniques for biological data retrieval, storage, and analysis that lead to a thorough understanding of the biological world. Countless options currently accessible in field of living sciences by the expansion of *in-silico* biology. Paradigm of life sciences has changed as a result of *in-silico* technologies, which offer researchers a valuable and affordable way to focus on *in-silico* techniques like homology modeling, epitope prediction, and molecular docking, which have impacted drug discovery and vaccine design. These techniques also provide previously unheard-of predictions and insights.

Keywords: β-cell Prediction, Drug development, Vaccine design, Infertility, *In-silico* approaches.

International Journal of Drug Delivery Technology (2023); DOI: 10.25258/ijddt.13.4.74

How to cite this article: Nikam PV, Kumar S, Gunjal SD, Kulkarni MH, Singh SP. Unlocking the Potential of *In-silico* Approaches: Drug Development and Vaccine Design. International Journal of Drug Delivery Technology. 2023;13(4):1606-1610.

Source of support: Nil.

Conflict of interest: None

INTRODUCTION

Researchers encounter new challenges every day, which pushes them to become more imaginative and practical. With its great diversification, biology currently includes several subfields, including microbiology, genetics, physiology, ecology, and others. It appears that scientists produce vast amounts of data regarding the genome, biomolecules, organisms, their interface, and progression. As a result, there is a budding necessitate for computational methods to gather, interpret, and analyze the data, which can occasionally be rather complex. Managing and analyzing vast volumes of biological data has become increasingly difficult, but the rapidly developing discipline of computational biology, or bioinformatics, has helped.[1] An interdisciplinary field-bioinformatics coalesce computer science, statistics, mathematics, biology, and other fields to create techniques for archiving, retrieving, and analyzing biological record.[2] "*In-silico*" is an alternate abbreviation that is much more widely recognized and has been used for 50 years.[3] "*In-silico*" approaches are forecasts that rely on computer models, as the term "*in-silico*" derives from the word "silicon," which is related to computers. American physical chemist Margaret Dayhoff (1925–1983) was a trailblazer in the application of computational techniques. Her contributions to this discipline have been so great that she has been referred to as the parent of bioinformatics" by David J. Lipman, ex-director of NCBI.[4] The integration of *in-silico* tools with genomic, proteomic, metabolomic, and transcriptomic data presents significant opportunities for comprehending diverse biological mechanisms and creating novel strategies for identifying, forecasting, and managing illnesses like cancer and neurological conditions, all while mitigating adverse consequences.[5] High-throughput computer systems have replaced traditional biological techniques since the development of *in-silico* technology, mostly because to cost, time, and energy savings. Rapid technological advancements led to the emergence of this subject and had a profound effect on proteomics, which is today regarded as the core of laboratories. These advancements also made it possible for researchers to quantify the genomes of many different animals.[6] Researchers need quick answers in situations like COVID-19, and bioinformatics is essential to achieving this goal and laying the groundwork that is required.[7] Moreover, informaticians

**Author for Correspondence: sanjaypharma20065@gmail.com*

have significantly aided the Human Genome Project and other omics studies by computerizing the research process.[8] The historical procedure for creating a novel medication was a protracted and challenging endeavor, typically requiring over $1.8 billion in expenses and more than a decade from the moment a potential drug candidate was pinpointed to the conclusion of clinical trials. The assessment of the potential drug candidate's toxicity and adverse effects primarily involved *in-vivo* and *in-vitro* techniques.[9] Conversely, the development of *in-silico* has reduced scale, time, and cost concerns while simultaneously improving the efficiency and accuracy of drug target and therapeutic medicine identification. It has also lessened the workload associated with evaluating a drug candidate's possible toxicity in animals.[10] Proteomics research now has new directions thanks to bioinformatics. The databases' proteomic and genomic data have given medical researchers the knowledge they need to understand metabolic pathways. Protein structures were previously ascertained experimentally using nuclear magnetic resonance (NMR) or X-ray crystallography,[11] which was not practical for all protein samples; however, today, target protein 3D structures can be inferred using computational structure prediction techniques like comparative modeling[12] or ab-initio modeling. This review requests the databases and *in-silico* methods created for drug and vaccine design. Additionally, it highlights the use of computational tools to clarify antigen sharing between humans and pathogens.

Common Approaches Involved in *In-silico*

Sequence database

In light of the massive amount of data generated, its organization and storage become the utmost necessity to which databases were constructed.[13] High-throughput sequencing techniques led to a rapid cohort of extensive genomic statistics. To make this information publicly available, numerous databases have been created worldwide. A biological sequence database is an extensive repository of information pertaining to biomolecules, including proteins and nucleic acids, wherein each biomolecule is identified by a distinct identifier. This review delves into the intricacies of protein databases, highlighting their significance as an authoritative means for exploration and understanding of the complex and dynamic nature of proteins.

Protein databases

Protein sequence databases are used as a storage and organization system for data pertaining to proteins. The first protein sequence catalog was the protein information resource, which was founded in 1984 by NBRF.[14]

Studies of protein diversity and function in a variety of organisms and biological processes are made easier by the UniProt database system. Over 227 million sequences are included in the UniProtKB database in UniProt release 2022-2023.[15] A collection of reviewed protein sequences and annotations is called the UniProt Knowledgebase (UniProtKB) (UniProtKB/Switzess-Prot). Each protein entry in this has a link to an overview of experimentally validated or computationally envisaged valuable information added by the connoisseur biocuration team.

The Protein Data Bank (PDB) is a globally acknowledged source of structural information about biological macromolecules. Researchers can submit data from X-ray crystallography and NMR spectroscopy to PDB, which houses these types of data and offers a variety of tools for protein analysis, visualization, and sequencing.[16]

Homology modeling

In recent years, NMR, X-ray crystallography, and cryo-electron microscopy (cryo-EM) have all gained prominence as crucial instruments for examining the three-dimensional configurations of proteins. While the field of proteomics has been advancing swiftly, there remains a substantial discrepancy between the quantity of experimentally ascertained protein three-dimensional structures and the known protein sequences. To bridge this gap, homology modeling has surfaced as a widely adopted alternative method for predicting protein structures.[17]

Utilizing preceding facts from structural resemblance amid other proteins, homology modeling, also referred to as comparative protein modeling, is a computational method for generating 3D structures of proteins from their amino acid sequences.[18] Using tools like BLAST, profile-profile alignments, and Hidden Markov Models (HMMs), the eligible templates are first found through sequence alignment in comparative modeling.[19] Programs like CLUSTAL W, CLUSTAL Omega, and MUSCLE can be used to obtain multiple sequence alignments.[20] One of the following four approaches can be used to create the 3D model: segment matching or coordinate reconstruction, artificial co-evolution, comparative modeling by spatial constraints, and modeling by assembly of rigid bodies.[21] An essential step in determining the functional stability and creation of the functional ligand binding sites is loop modeling.[22] It is carried out using conformational search techniques or database search techniques. Using rotamer libraries and scoring functions and software like SCRWL, OPUS-Rota-2, and FASPR, side chains are added to the model in the next step. The last stage was to improve the protein structure's quality. This phase, referred to as "model optimization," improves the final model's quality by removing unfavorable non-bonded interactions and optimizing bond geometry.[23,24] To prevent steric collisions between atoms, energy minimization techniques such as CHARMM, AMBER, and GROMOS are employed; molecular dynamics and Monte Carlo simulations can be used for additional optimization.[25] By examining the 3D conformations and statistical potentials of the model, programs like VERIFY3D and PROSAII assess the spatial accuracy of the model. Protein structural modeling has advanced significantly in recent years, offering biologists numerous opportunities to further their research. Scientists can now overcome production challenges with informed decision-making thanks to homology modeling. Besides, homology modeling has emerged as a functional tool in a meadow of realistic drug design, chiefly for high-throughput *in-silico*

assortment and recreation approaches. This has created new opportunities for the field's researchers to accomplish their objectives more quickly and successfully.[26]

Molecular docking

Here, we delve into the computational analysis of interactions between two molecules. Specifically, one molecule serves as a small ligand, while the other acts as a macromolecular protein receptor. Molecular docking stands out as a preeminent computational structure-based approach for drug design, a methodology that gained prominence since its inception in the early 1980s.[27] Through the characterization of the behavior of ligand molecules within the binding site of target proteins, the molecular docking approach plays a crucial role in enhancing our comprehension of fundamental biochemical processes. This methodology facilitates the exploration of atomic-level interactions between the ligand and the protein, thereby contributing valuable insights to the field.[28] A systematic process takes place in molecular docking, beginning with the crucial step of protein formulation**.** This involves determining the target structure experimentally using Molecular docking is a methodical process that starts with the important step of protein formulation. In order to do this, the target structure must be determined experimentally using methods like X-ray crystallography or NMR. With differing degrees of accuracy, homology models can also be utilized in the absence of this data. The 3D structure is obtained from the PDB and pre-processed for stability and missing residues.[29,30] Ligands can be obtained from PUB Chem and ZINC databases, but if their 3D coordinates are unavailable, they can be created using tools based on their 2D structures such as Avogadro, Chem-Sketch or Chem-Draw. Docking, the last phase looks at how the ligand and protein interact. To determine the optimal ligand pose, search algorithms and scoring functions are needed. An RMSD of less than two angstroms indicates a successful docking prediction. The accuracy of the docking prediction is evaluated using this calculation. Ki values or inhibition constants can be used to assess the ligand's potency To put it briefly, molecular docking is an effective technique that leads to new avenues for biological research and gives scientists a better understanding of the molecular interactions at the core of life[29]. Using programs like MolDock or DoGSiteScorer, potential binding sites are found through active site prediction in the following stage.[31]

Exploring the Unrivalled Contributions of *In-silico* in Drug Development, and Vaccine Designing

Drug discovery

The primary objective of the drug design and development process is to identify new compounds that are both safe and efficacious. Historically, drug discovery was a challenging, expensive, and often inefficient undertaking. However, recent advancements, particularly in technologies such as *in-silico* drug design, have made the process more attainable. The evolution of the drug discovery process aligns with contemporary trends, benefiting from enhanced specificity and efficiency in databases developed through the integration of big data and advancements in information technology.[32] The most popular *in-silico* methods in the drug development process are homology modeling, molecular simulations, molecular docking, and epitope prediction. Using these techniques can help save time and resources by constructing precise models of the target molecule and identifying the optimal binding orientation of a drug candidate. Antimicrobial compound structures were taken from Pubchem, and MRSA protein structures were taken from the RGCB PDB database. Protohypericin, galangin, berberine, and berbamine were found to be potent compounds with strong binding affinities to the targeted proteins through docking experiments. Promising inhibition of significant *Staphylococcus aureus* proteins was demonstrated by *Beberis vulgaris*, *Hibiscus sabdariffa*, *Chelidonium majus*, *Mahonia aquifolium*, *Hypericum perforatum*, and *Rheum ribes*. These substances have the potential to be antibiotics because they have few side effects on human health. Since it was established that COVID-19 infection could still occur in people even in the presence of the vaccine.[33] To find inhibitors of SARS-CoV-2 that aim at particular protein targets. Thirteen putative protein targets were found after a thorough literature review. After 501 medicinal phytochemicals were screened, 26 compounds with remarkable anti-SARS-CoV-2 efficacy were found. Notably, Gmelina arborea's 4,8-dihydroxysesamin and arboreal showed encouraging activity against a variety of targets. Their higher affinity for the nucleocapsid target was revealed through comparative analysis with established medications. All things considered, these substances show great promise in blocking SARS-CoV-2.[34]

Vaccine designing

Infectious organisms were partially inactivated or attenuated to create conventional vaccinations. Although this method was advantageous at the time, it took more than five to fifteen years and resulted in adverse effects like fever and hypersensitivity. One solution to the problems with conventional vaccination methods has been proposed: the development of novel vaccine candidates.[35] The field of computational *in-silico* immunoinformatics aids in the creation of novel vaccines. Advances in immunology and computational biology for the identification of immunogenic epitopes can trigger an immune response, have greatly aided in the design and development of vaccines. Using *in-silico* methods to predict a vaccine candidate's potential efficacy in advance, such as molecular simulation and epitope prediction, can expedite the vaccine development process. Epitope prediction has become crucial in identifying the epitopes that can activate T and B cell responses.[36,37] An epitope, also known as an antigenic determinant, is an exposed surface area of an antigen that, upon binding an antibody, elicits an immune response. Specific antibodies (Abs) recognize antigenic determinants, which are discrete regions of an antigen (Ag).[38]

Epitope prediction for B cells

B-cell epitopes refer to clusters of amino acids on the surface of proteins that are recognized by B-cell receptors or secreted

antibodies, eliciting a humoral or cellular immune response. The intricate spatial arrangement of B-cell epitopes can be broadly categorized into two groups: continuous (linear or sequential) and discontinuous (nonlinear or conformational). Conformational B-cell epitopes consist of non-sequential amino acid residues in the protein's main structure that fold in nearby regions. On the other hand, linear epitopes, also known as continuous epitopes, are short peptide segments of an antigen composed of successive amino acid residues, typically not exceeding 15 amino acids in length.[39-41]

T-Cell epitope prediction

A vital immunology endeavor in which the ultimate goal is to determine peptides within an antigen that is most concise and capable of eliciting a strong response from CD-4 or CD-8 T-cells.[42]

By using a logical design that saves time and money, *In-silico* also aids in the development of vaccines. These computer simulations are being used to test antiviral small compounds and peptides due to their higher selectivity and a decreased tendency to elicit unwanted immune responses. Computational methods were employed to create a vaccine against drug-resistant *Mycobacterium tuberculosis* (Mtb) strains. They concentrated on a multi-epitope subunit vaccine made of Mtb antigens that have been experimentally verified.[43] IEDB was used to predict the epitopes on B and T-cells, and bioinformatics techniques were used to refine and validate the 3D structure. To improve the vaccine, docking with TLR-3 was carried out and a number of factors were taken into account, such as molecular docking scores, physiochemical properties, allergenicity, antigenicity, and solubility. *In-vitro* positive immune cell responses were shown by *in-silico* immune simulations. According to the research, this multi-epitope vaccine is a promising candidate for a tuberculosis vaccine because it may trigger both humoral and cellular immune reactions sought to create an *in-silico* vaccine based on epitopes to protect against the fungal infection aspergillosis. Predicted B and T cell epitopes were used in molecular docking studies with corresponding receptors. Linear B cell epitopes were identified from two short peptide chains based on their physicochemical properties.[44,45] The most likely T cell epitope was determined to be the peptide sequence 221LDLFQNAFTQLADVS235, which together with the peptide-MHC, T cell receptor, and CD4 molecule complex formed a stable dock structure. To find out if these proposed epitopes are suitable for peptide-based aspergillosis vaccinations, more experimental validation is needed. Use of different immunoinformatics skills to develop a multi-epitope vaccine against *Legionella pneumophila*.[46-50]

CONCLUSION

This review describes *in-silico* approaches in drug development and vaccine design; it mentions T and B cells epitope predictions, molecular docking and sequence database.

REFERENCES

1. Fielden MR, Matthews JB, Fertuck KC, Halgren RG, Zacharewski TR. *In-silico* approaches to mechanistic and predictive toxicology: an introduction to bioinformatics for toxicologists. Critical reviews in toxicology. 2002; 32(2): 67-112.
2. Mehmood MA, Sehar U, Ahmad N. Use of bioinformatics tools in different spheres of life sciences. Journal of Data Mining in Genomics & Proteomics.2014; *5*(2): 1.
3. Barker WC, Garavelli JS, Huang HM, Garvey PB, Orcutt BC & Srinivasarao GY. The protein information resource (PIR). Nucleic acids research. 2000; *28*(1): 41-44.
4. Gauthier J, Vincent AT, Charette SJ, Derome N. A brief history of bioinformatics: Briefings in bioinformatics. 2019; *20*(6): 1981-1996.
5. Barh D, Yiannakopoulou EC, Salawu EO, Bhattacharjee A, Chowbina S, Nalluri JJ, Ghosh P, Azevedo V. *In-silico* disease model: from simple networks to complex diseases. Animal Biotechnology. 2020; 441–460.
6. Bayat A. Science, medicine and the future: Bioinformatics. BM. British Medical Journal. 2002; 324(7344):1018.
7. Mitra D, Mitra D, Bensaad MS, Sinha S, Pant K, Pant M. Evolution of Bioinformatics and its impact on modern bio-science in the twenty-first century: special attention to pharmacology, plant science and drug discovery. Computational Toxicology. 2022; 24: 100248.
8. Maojo V, Fritt M, Martin-Sanchez F, De la Iglesi, D, Cachau RE, Garcia-Remesal M, Kulikowski C. Nanoinformatics: developing new computing applications for nanomedicine. Computing. 2012; 94(6): 521-539.
9. Shaker B, Ahmad S, Lee J, Jung C, & Na D. *In-silico* methods and tools for drug discovery. Computers in biology and medicine. 2021; *137*: 104851.
10. Madden JC, Enoch SJ, Paini A, Cronin MT. A review of *in-silico* tools as alternatives to animal testing: principles, resources and applications. Alternatives to Laboratory Animals.2020; 48(4): 146-172
11. Jhoti H, Leach AR. Book:Structure-based drug discovery. 2007; 10:1007
12. Cavasotto CN, Phatak S. Homology modeling in drug discovery: current trends and applications. Drug discovery today. 14(13): 676-683.
13. Diniz WJS, Canduri F. Bioinformatics: an overview and its applications. Genet Mol Re.2017; 16(1): 10-4238.
14. Wu CH, Huang H, Arminski L, Castro-Alvear J, Chen Y, Hu ZZ. The Protein Information Resource: an integrated public resource of functional annotation of proteins. Nucleic acids research.2002; 30(1): 35-37
15. UniProt C. The Universal Protein Knowledgebase. Nucleic acids research. 2023; 51(D1): D523–D531.
16. Nudin A, Ellmi A, Petalcorin MI, Lu ZH, Shafqat N. Comparative Proteomic Analysis.2018.
17. Hameduh T, Haddad Y, Adam V, Heger Z.Homology modeling in the time of collective and artificial intelligence. Computational and Structural Biotechnology Journal.2020;18: 3494-3506.
18. Wadood A, Ahmed N, Shah L, Ahmad A, Hassan H, Shams S. *In-silico* drug design: An approach which revolutionarised the drug discovery process. OA Drug Design Development and Delivery.2013; 1(1): 3.
19. Pitman MR, Menz RI. Methods for protein homology modeling. Applied mycology and biotechnology.2006; 6: 37-59.
20. Johnson LS, Eddy SR, Portugaly E. Hidden Markov model speed heuristic and iterative HMM search procedure. BMC bioinformatic.2010; 11(1):1-8.
21. Fiser A, Clifton NJ. Template-based protein structure modeling.

Methods in molecular biology.2010; 673: 73–94.
22. Xiang Z. Advances in homology protein structure modeling. Current Protein and Peptide Scienc.2006; 7(3): 217-227.
23. Peitsch MC.About the use of protein models: Bioinformatics.2002; 18(7): 934-938.
24. Krivov GG, Shapovalov MV, Dunbrack Jr R L. Improved prediction of protein side-chain conformations with SCWRL4. Proteins. Structure, Function, and Bioinformatics.2009; 77(4): 778-795.
25. Hong SH, Joung I, Flores-Canales JC, Manavalan B, Cheng Q, Heo S, Lee J. Protein structure modeling and refinement by global optimization in CASP12. Proteins: Structure, Function, and Bioinformatics.2018; 86 : 122-135.
26. Las SD, Das S, Sillitoe I, Orengo C. An overview of comparative modeling and resources dedicated to large-scale modeling of genome sequences. Acta crystallographica. Section D, Structural biology.2017; 73(Pt 8): 628–640.
27. Stanzione F, Giangreco I, Cole JC. Use of molecular docking computational tools in drug discovery. Progress in Medicinal Chemistry.2021; 60: 273-343.
28. McConkey BJ, Sobolev V, Edelman M.The performance of current methods in ligand–protein docking. Current Science. 2002; 83(7): 845–856.
29. Morris GM, Lim-Wilb M. Molecular docking: Molecular modeling of proteins.2008; *443*: 365-382.
30. Vasan OK, Chandrakant MA, Chandrashekhar KV, Babasaheb GV, Dnyandev KM. A review on molecular docking. International Research Journal of Pure and Applied Chemistry.2021;22(3): 60-68.
31. Volkamer A, Kuhn D, Grombacher T, Rippmann F, Rarey, M. Combining global and local measures for structure-based druggability predictions. Journal of chemical information and modeling.2012; 52(2): 360-372.
32. Terstappen GC, Reggiani A. *In-silico* research in drug discovery. Trends in pharmacological science.2001; *22*(1) :23-26.
33. Dorcheh FA, Balmeh N, Sanjari S. *In-silico* investigation of antibacterial herbal compounds in order to find new antibiotic against Staphylococcus aureus and its resistant subtypes. Informatics in Medicine Unlocked. 2022; 28: 100843.
34. Roshni J, Vaishali R, Ganesh KS, Dharani N, Alzahrani KJ, Banjer HJ.Multi-target potential of Indian phytochemicals against SARS-CoV-2: a docking, molecular dynamics and MM-GBSA approach extended to Omicron B. 1.1. 529. Journal of Infection and Public Health.2022; 15: 662-669
35. Kardani K, Bolhassani A, Namvar A.An overview of *in-silico* vaccine design against different pathogens and cancer. Expert review of vaccines. 2020; 19(8): 699–726.
36. Martinez L, Malaina I, Salcines-Cuevas D, Teran-Navarro H, Zeoli A, Alonso S, M De la Fuent I, Gonzalez-Lopez E, Ocejo-Vinyals JG, Gozalo-Margüello M, Calvo-Montes J, Alvarez-Dominguez C. First computational design using lambda-superstrings and in vivo validation of SARS-CoV-2 vaccine. Scientific reports.2022; 12(1) :6410.
37. Patronov A, Doytchinova I. T-cell epitope vaccine design by immunoinformatics. Open biology,.3(1): 120-139.
38. Bosshard, Hans R. "Epitope mapping with peptides." Peptides: Synthesis, structures, and applications. Edited by B. Gutte. Zurich, Switzerland (1995): 419.
39. Getzoff ED, Tainer JA, Lerne RA, Geysen, HM. The chemistry and mechanism of antibody binding to protein antigens. Advances in immunology.1988; 43: 1–98.
40. Potocnakova L, Bhide M, Pulzova LB. An introduction to b-cell epitope mapping and *in-silico* epitope prediction. Journal of immunology research. 2016: 676-830.
41. Lundegaard C, Lund O, Keşmir C, Brunak S, Nielsen M. Modeling the adaptive immune system: predictions and simulations. Bioinformatics.2007;23(24): 3265-3275.
42. Ahmed RK, & Maeurer MJ.T-cell epitope mapping. Epitope Mapping Protocols: Second Edition. 2009: 427-438.
43. Bibi S, Ullah I, Zhu B, Adnan M, Liaqat R, Kong WB, Niu S. *In-silico* analysis of epitope-based vaccine candidate against tuberculosis using reverse vaccinology. Scientific reports. 2021;11(1): 1-16.
44. Basu A. *In-silico* epitope-based vaccine prediction against fungal infection aspergillosis. Challenges.2022;13(2): 29.
45. Adimulapu AK, Devhare LD, Patil A, Chachda NO, Dharmamoorthy G. Design and Development of Novel Mini Tablet Cap Technology for the Treatment of Cardiovascular Diseases. International Journal of Drug Delivery Technology. 2023;13(3):801-806.
46. Umar A, Liaquat S, Fatima I, Rehman A, Rasool D, Alshammari A, Alharbi M, Rajoka MSR, Khurshid M, Ashfaq UA, Haque A.Vaccinomics to Design a Multiepitope Vaccine against *Legionella pneumophila*. BioMed research international. 2022; 4975721.
47. Gnana RPM, Devhare LD, Dharmamoorthy G, Khairnar MV, Prasidha R. Synthesis, Characterisation, Molecular Docking Studies and Biological Evaluation of Novel Benzothiazole Derivatives as EGFR Inhibitors for Anti-breast Cancer Agents. International Journal of Pharmaceutical Quality Assurance. 2023;14(3):475-480.
48. Deshmukh MN, Uplanchiwar VP, Thakare VM, Mane NS, Gaikwad SN, Dighade NR, Mehta HD, Bakal R, Umate P. Development and Validation of HPLC Method for Estimation of Some Active Analytes in Combined Dosage form an Application to In-vitro Dissolution Studies. International Journal of Pharmaceutical Quality Assurance. 2023;14(2):334-339.
49. Devhare LD and Gokhale N. Antioxidant and antiulcer property of different solvent extracts of cassia tora linn. Research journal of pharmacy and technology. 2022;15(3):1109-1113
50. Saumya D, Kumar DM, Anamika. Antibacterial and Antifungal Potential of Berberine Isolated from Stem of Berberis aristata DC. International Journal of Drug Delivery Technology. 2023;13(2):454-460.